Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 3,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total value of $421,440.00. Following the transaction, the insider now owns 141,782 shares of the company's stock, valued at $19,917,535.36. The trade was a 2.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The shares were sold at an average price of $146.04, for a total transaction of $149,837.04.
• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total value of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Price Performance

NASDAQ NTRA traded down $5.18 during trading on Tuesday, hitting $133.08. 732,354 shares of the stock traded hands, compared to its average volume of 1,378,458. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The firm has a 50-day simple moving average of $156.27 and a 200-day simple moving average of $151.65. The company has a market capitalization of $17.99 billion, a P/E ratio of -75.21 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. As a group, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on NTRA shares. Canaccord Genuity Group restated a "buy" rating and issued a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Piper Sandler raised their price objective on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. Robert W. Baird boosted their price objective on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Royal Bank of Canada began coverage on shares of Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $178.12.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently made changes to their positions in NTRA. Wilmington Savings Fund Society FSB purchased a new position in Natera in the third quarter worth about $385,000. Everence Capital Management Inc. purchased a new position in shares of Natera in the 4th quarter worth approximately $573,000. Smartleaf Asset Management LLC increased its position in shares of Natera by 50.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after purchasing an additional 220 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Natera by 87.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company's stock valued at $8,621,000 after buying an additional 31,649 shares during the period. Finally, SeaBridge Investment Advisors LLC bought a new stake in Natera in the fourth quarter worth $2,894,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.